Insider Selling: ADMA Biologics Inc (NASDAQ:ADMA) Director Sells 194,749 Shares of Stock

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) Director Steve Elms sold 194,749 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director now directly owns 87,330 shares in the company, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Steve Elms also recently made the following trade(s):

• On Thursday, June 12th, Steve Elms sold 92,941 shares of ADMA Biologics stock. The shares were sold at an average price of $21.69, for a total transaction of $2,015,890.29.
• On Friday, June 13th, Steve Elms sold 137,931 shares of ADMA Biologics stock. The shares were sold at an average price of $20.82, for a total transaction of $2,871,723.42.

ADMA Biologics Price Performance

NASDAQ:ADMA traded down $0.39 on Friday, reaching $17.74. 5,642,596 shares of the company's stock traded hands, compared to its average volume of 3,708,871. The stock has a 50-day simple moving average of $20.94 and a 200-day simple moving average of $18.82. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. ADMA Biologics Inc has a 12 month low of $10.21 and a 12 month high of $25.67. The firm has a market cap of $4.24 billion, a PE ratio of 20.87 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same period in the previous year, the business earned $0.08 earnings per share. The business's quarterly revenue was up 40.2% on a year-over-year basis. Equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock worth $865,000 after purchasing an additional 645 shares during the period. Cetera Investment Advisers lifted its stake in ADMA Biologics by 1.3% during the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock valued at $1,002,000 after acquiring an additional 670 shares during the period. Oregon Public Employees Retirement Fund boosted its stake in shares of ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock worth $954,000 after buying an additional 700 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock valued at $1,323,000 after buying an additional 711 shares in the last quarter. Finally, Summit Investment Advisors Inc. grew its position in shares of ADMA Biologics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock valued at $404,000 after purchasing an additional 746 shares during the period. Institutional investors own 75.68% of the company's stock.

Wall Street Analyst Weigh In

ADMA has been the topic of several recent research reports. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th. Finally, Raymond James Financial increased their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, ADMA Biologics presently has an average rating of "Moderate Buy" and an average price target of $24.25.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.